Precision pharmacology for Alzheimer’s disease
- 16 February 2018
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 130, 331-365
Abstract
No abstract availableKeywords
Funding Information
- AXA Research Fund
- Rotary Club Livorno “Mascagni”/The Rotary Foundation (GG1758249)
- The Semmes Foundation
This publication has 292 references indexed in Scilit:
- The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaquesActa Neuropathologica, 2013
- Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using MetabolomicsPLOS ONE, 2013
- Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier ProteinsPLOS ONE, 2013
- Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 miceBMC Neuroscience, 2013
- Power and Pitfalls of the Genome-Wide Association Study Approach to Identify Genes for Alzheimer’s DiseaseCurrent Psychiatry Reports, 2011
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous systemAnnals of Neurology, 2009
- Substrate specificity of γ-secretase and other intramembrane proteasesCellular and Molecular Life Sciences, 2008
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991